The submission of an IND application is a critical regulatory step in drug development, indicating that Alzamend Neuro is progressing with its clinical trials. This news is likely to be viewed positively by investors as it demonstrates advancement in the company's pipeline, which could lead to future revenue streams if the drug is successful. The focus on PTSD, a significant and underserved medical condition, could also attract attention to the stock.